# A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

Source: https://onco.cc/trials/nct06687941/  
OnCo record `nct06687941` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of AST-201 run by Aptamer Sciences, Inc., now recruiting.

## Summary

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors is a phase 1 interventional study registered as NCT06687941 by Aptamer Sciences, Inc., with 70 participants planned, started 2025-03-11. Conditions recorded: Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung and Liver Neoplasms. Interventions recorded: AST-201.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06687941
- Phase: 1
- Setting: A Multi-center, Open-label, Dose Escalation and Expansion, Phase 1 Study to Evaluate the Tolerability, Safety and Pharmacokinetics of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
- Sponsor: Aptamer Sciences, Inc.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06687941: https://clinicaltrials.gov/study/NCT06687941

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [AST-201](https://onco.cc/drugs/ast-201/)
- companies: [Aptamer Sciences](https://onco.cc/companies/aptamer-sciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06687941.json